Detalhe da pesquisa
1.
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Blood
; 143(19): 1931-1936, 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38364112
2.
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.
Blood
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691678
3.
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Blood
; 142(20): 1697-1707, 2023 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37595359
4.
Acute myeloid leukaemia.
Lancet
; 401(10393): 2073-2086, 2023 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068505
5.
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Blood
; 138(26): 2753-2767, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724563
6.
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
Am J Hematol
; 98(12): 1847-1855, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37671649
7.
Assessment of Minimal Residual Disease in Standard-Risk AML.
N Engl J Med
; 374(5): 422-33, 2016 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26789727
8.
Transplant in older adults with AML: genomic wheat and chaff.
Blood
; 139(24): 3459-3461, 2022 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35708723
9.
AML in the elderly-A global view.
Br J Haematol
; 203(5): 760-773, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37822071
10.
Delving the depths of measurable residual disease negativity in acute myeloid leukemia.
Haematologica
; 107(12): 2776-2778, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35295082
11.
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?
Blood
; 124(23): 3345-55, 2014 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-25049280
12.
An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts.
Br J Haematol
; 170(1): 80-4, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25876768
13.
No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.
Blood
; 131(4): 468-471, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29229596
14.
Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults.
Br J Haematol
; 186(1): 130-133, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30520018
15.
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
J Clin Oncol
; 42(10): 1158-1168, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38215358
16.
Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.
Blood Adv
; 7(16): 4381-4394, 2023 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37267435
17.
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Blood Adv
; 7(16): 4539-4549, 2023 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37171402
18.
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Leukemia
; 37(10): 2066-2072, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37558736
19.
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
Lancet Haematol
; 10(9): e767-e776, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37572683
20.
Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis.
Leukemia
; 36(12): 2817-2826, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36261575